Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.32 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2405836 | 0.82 | ABAT (0.38) | SMN1; SMN2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| Hydrochloric Acid SCHEMBL9152336 | 0.80 | ABAT (0.37) | SMN1; SMN2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL6421988 | 0.78 | BRD4 (0.44) | SMN1; SMN2CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL6270700 | 0.77 | BCHE (0.37) | SMN1; SMN2BCHEALDH1A1GAA | |
| SCHEMBL6267871 | 0.76 | KMT2A (0.31) | SMN1; SMN2 | |
| SCHEMBL6268314 | 0.76 | SMN1; SMN2 (0.42) | SMN1; SMN2BCHEALDH1A1GAA | |
| SCHEMBL6268319 | 0.74 | GAA (0.31) | SMN1; SMN2GAA | |
| SCHEMBL6268517 | 0.72 | MAPK1 (0.30) | — | |
| SCHEMBL6271775 | 0.72 | BCHE (0.31) | BCHE | |
| SCHEMBL4067739 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070166296-A1 | Therapeutic Systems | ENZACTA R & D LIMITED | 2007-07-19 | — | — | US | disclosed |
| US-7138122-B2 | Therapeutic systems | ENZACTA R & D LIMITED (GB) | 2006-11-21 | — | — | US | disclosed |
| EP-0988059-B1 | HUMAN QUINONE REDUCTASE 2 CONJUGATES FOR ADEPT AND GDEPT | ENZACTA R & D LTD (GB) | 2005-12-07 | — | — | EP | disclosed |
| US-6867231-B1 | Therapeutic systems | ENZACTA R & D LIMITED (GB) | 2005-03-15 | — | — | US | disclosed |
| EP-1468698-A2 | HUMAN QUINONE REDUCTASE 2 CONJUGATES FOR ADEPT AND GDEPT | ENZACTA R & D LIMITED (GB) | 2004-10-20 | — | — | EP | disclosed |
| US-20030086933-A1 | Therapeutic systems | ENZACTA R & D LIMITED | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070166296-A1 | Therapeutic Systems | NQO2, NQO1, NAPRT | SMN1; SMN2 513/4885BCHE 2845/4885CHRNB2 796/4885 |
| US-20030086933-A1 | Therapeutic systems | NQO2, NQO1, NAPRT | SMN1; SMN2 513/4885BCHE 2845/4885CHRNB2 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.